Amanita muscaria (also known as fly agaric) is a type of mushroom with hallucinogenic properties. It is also not listed on any schedule of the Controlled Substances Act (CSA). So of course, people want to make and sell it. But what is it? And is it legal? Amanita muscaria (fly agaric) Amanita muscaria is a
Last week, the Oregon Health Authority (OHA) awarded a pair of psilocybin manufacturer licenses. First two! Congrats to Tori Arbrust of Satori Farms PDX, and Andres Met of Satya Therapeutics, known to many of us from the Oregon cannabis program. We should also congratulate OHA, which had aimed to issue manufacturing licenses by the end
Among the emerging medical uses for MDMA and psilocybin is their relative dimethyltryptamine (DMT). Although a Schedule I drug in the United States, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Much of this research is occurring outside of
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so
Our marketing people somehow determined that I should write a piece comparing Oregon’s new psilocybin program with The Last of Us– which is a zombie show about a global pandemic caused by a mass fungal infection. Apparently this type of content gets a lot of eyeballs. I said: I don’t want to watch a whole
Over the last year and change, I’ve written quite a bit about how the ketamine telehealth industry was in store for a rude awakening when the COVID-19 public health emergency (PHE) declaration ended. My most recent post, entitled “Bad News for Ketamine Telehealth” predicted an imminent shakeup in the industry due to the looming end
Last summer, my colleague, Ethan Minkin, published a post entitled “Utah Ketamine Clinics Face New Patient Monitoring Law.” The law in question applied a host of new requirements on anesthesia or sedation providers, which created a series of hurdles for ketamine clinics. A few weeks ago, a Utah state legislator submitted a bill that would
Earlier this week, President Joe Biden’s administration made an announcement that signals potential bad news for the ketamine telehealth industry. Effective May 11, 2023, the federal COVID-19 public health emergency (PHE) declaration will end. This is likely to plunge the entire ketamine telehealth industry into chaos in the coming months. If you are unfamiliar with
It seems that the Oregon psilocybin program is off to a slow start. The Oregon Health Authority (OHA) did a good job meeting the Measure 109 rulemaking and development deadlines, including by opening the license application portal back on January 2. Still, a slew of factors, some of them structural, have tempered program launch. The
